PMID- 16967492
OWN - NLM
STAT- MEDLINE
DCOM- 20070227
LR  - 20220331
IS  - 0148-639X (Print)
IS  - 0148-639X (Linking)
VI  - 35
IP  - 1
DP  - 2007 Jan
TI  - Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a 
      prospective pilot trial.
PG  - 66-9
AB  - We studied the effect of rituximab in allowing a reduction in dose of intravenous 
      immune globulin (IVIg) in six patients with IVIg-dependent, relapsing immune 
      polyneuropathy. Rituximab (375 mg/m(2) intravenously each week for 4 weeks) was 
      administered in a prospective, open-label design to two patients with chronic 
      inflammatory demyelinating polyneuropathy (CIDP), two with multifocal motor 
      neuropathy (MMN), one with neuropathy and anti-myelin-associated glycoprotein 
      (MAG) antibody neuropathy, and one with Sjogren syndrome (SS) ataxic neuropathy. 
      The primary endpoint was a reduced cumulative IVIg dosage by at least 25% at 1 
      year after rituximab therapy compared to the previous year. Secondary endpoints 
      included an improved summed strength score by at least 5 points on the Medical 
      Research Council scale, an increased sensory score by at least 4 points, or an 
      improved Rankin disability score by at least 1 grade. Total IVIg dosage decreased 
      by greater than 25% in one patient with SS neuropathy and one with MMN; the 
      dosage was unchanged in one with CIDP, slightly reduced in the patient with 
      anti-MAG neuropathy, and increased in one with CIDP and another with MMN. There 
      was no improvement in secondary endpoints. No adverse events occurred. In this 
      small prospective study, rituximab did not reduce IVIg requirements in the 
      majority of patients with IVIg-dependent, immune-mediated polyneuropathies.
FAU - Gorson, Kenneth C
AU  - Gorson KC
AD  - Department of Neurology, Caritas St. Elizabeth's Medical Center, Tufts University 
      School of Medicine, 736 Cambridge Street, Boston, Massachusetts 02135, USA. 
      kengorson@comcast.net
FAU - Natarajan, Neela
AU  - Natarajan N
FAU - Ropper, Allan H
AU  - Ropper AH
FAU - Weinstein, Robert
AU  - Weinstein R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Myelin-Associated Glycoprotein)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Endpoint Determination/methods
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Immunologic Factors/administration & dosage
MH  - Motor Neuron Disease/drug therapy/immunology/physiopathology
MH  - Myelin-Associated Glycoprotein/immunology
MH  - Peripheral Nerves/*drug effects/*immunology/physiopathology
MH  - Pilot Projects
MH  - Polyradiculoneuropathy/*drug therapy/*immunology/physiopathology
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/drug 
      therapy/immunology/physiopathology
MH  - Prospective Studies
MH  - Rituximab
MH  - Sjogren's Syndrome/drug therapy/immunology/physiopathology
MH  - Treatment Outcome
EDAT- 2006/09/13 09:00
MHDA- 2007/02/28 09:00
CRDT- 2006/09/13 09:00
PHST- 2006/09/13 09:00 [pubmed]
PHST- 2007/02/28 09:00 [medline]
PHST- 2006/09/13 09:00 [entrez]
AID - 10.1002/mus.20664 [doi]
PST - ppublish
SO  - Muscle Nerve. 2007 Jan;35(1):66-9. doi: 10.1002/mus.20664.